Synthesis and pharmacological evaluation of new pyrazolidine-3,5-diones as AT1 angiotensin II receptor antagonists

Journal of Medicinal Chemistry

Volumn 43, Issue 14, 2000, Pages 2685-2697

  Le Bourdonnec, Bertrand ^a,b   Meulon, Emmanuelle ^a   Yous, Saïd ^a   Goossens, Jean François ^a   Houssin, Raymond ^a   Hénichart, Jean Pierre ^a  

^a UNIV LILLE   (France)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 3 [[2' (1H TETRAZOL 5 YL) (1,1' BIPHENYL) 4 YL]METHYL] 2,3 DIAZASPIRO[4.4]NONANE 1,4 DIONE; 3 [[2'(BENZOYLAMINOSULFONYL)(1,1' BIPHENYL) 4 YL]METHYL] 2 BUTYL 2,3 DIAZASPIRO[4.4]NONANE 1,4 DIONE; ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN; PHENYLBUTAZONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANGIOTENSIN II; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; CALCIUM; HUMANS; LIGANDS; PYRAZOLES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TUMOR CELLS, CULTURED;

EID: 0034644277     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9904147     Document Type: Article

References (38)

1. Ferrario, C. M. The Renin-Angiotensin System: Importance in Physiology and Pathology. J. Cardiovasc. Pharmacol. 1990, 15 (Suppl. 3), S1-S5.
2. Waeber, B.; Nussberger, J.; Brunner, H. R. Angiotensin-Converting-Enzyme Inhibitors in Hypertension. In Hypertension: Pathophysiology, Diagnosis and Management; Laragh, J. H., Brenner, B. M., Eds; Raven Press: New York, 1990; pp 2209-2232.
3. Lindgren, B. R.; Andersson, R. G. G. Angiotensin-Converting Enzyme Inhibitors and Their Influence on Inflammation, Bronchial Reactivity and Cough. Med. Toxicol. Adverse Drug Exp. 1989, 4, 369-380.
4. (a) Timmermans, P. B. M. W. M.; Carini, D. J.; Chiu, A. T.; Duncia, J. V.; Price, W. A., Jr.; Wells, G. J.; Wong, P. C.; Wexler, R. R.; Johnson, A. L. Nonpeptide Angiotensin II Receptor Antagonists. Am. J. Hypertens. 1990, 3, 599-604.
5. (b) Levens, N. R.; de Gasparo, M.; Wood, J. M.; Bottari, S. P. Could the Pharmacological Differences Observed Between Angiotensin II Antagonists and Inhibitors of Angiotensin Converting Enzyme be Clinically Beneficial? Pharmacol. Toxicol. 1992, 71, 241-249.
6. de Gasparo, M.; Husain, A.; Alexander, W.; Catt, K. J.; Chiu, A. T.; Drew, M.; Goodfriend, T.; Harding, J. W.; Inagami, T.; Timmermans, P. B. M. W. M. Proposed Update of Angiotensin Receptor Nomenclature. Hypertension 1995, 25, 924-927.
7. Timmermans, P. B. M. W. M.; Benfield, P.; Chiu, A. T.; Herblin, B. F.; Wong, P. C.; Smith, R. D. Angiotensin II receptors and functional correlates. Am. J. Hypertens. 1992 (Suppl.), 221S-225S.
8. (a) Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R. E.; Dzau, V. J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. J. Biol. Chem. 1993, 268, 24539-24542.
9. (b) Kambayashi, Y.; Bardhan, S.; Takahashi, K.; Tsuzuki, S.; Inui, H.; Hamakubo, T.; Inagami, T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268, 24543-24546.
10. 2 de l'Angiotensine II. Therapie 1998, 53, 213-216.
11. (a) Duncia, J. V.; Chiu, A. T.; Carini, D. J.; Gregory, G. B.; Johnson, A. L.; Price, W. A.; Wells, G. J.; Wong, P. C.; Calabrese, J. C.; Timmermans, P. B. M. W, M. The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives. J. Med. Chem. 1990, 33, 1312-1329.
12. (b) Carini, D. J.; Duncia, J. V.; Johnson, A. L.; Chiu, A. T.; Price, W. A.; Wong, P. C.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: N-[(Benzyloxy)benzyl]imidazoles and Related Compounds as Potent Antihypertensives. J. Med. Chem. 1990, 33, 1330-1336.
13. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella, J. B., III.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S. E.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylmethyl)-imidazoles as Potent, Orally Active Antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
14. Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Pierce, M. E.; Price, W. A.; Smith, R. D.; Wells, G. J.; Wong, P. C.; Wexler, R. R.; Johnson, A. L.; Timmermans, P. B. M. W. M. DuP 753 Losartan Potassium (MK-954). Drugs Future 1992, 17, 326-331.
15. (a) Ashton, W. T. Nonpeptide Angiotensin II Receptor Antagonists. Exp. Opin. Invest. Drugs 1994, 3, 1105-1142.
16. (b) Buhlmayer, P. Angiotensin II Antagonists: Patent Activity since the Discovery of DuP 753. Curr. Opin. Ther. Pat. 1992, 2, 1693-1718.
17. (c) Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656.
18. 1 Angiotensin II Receptor Antagonists. J. Med. Chem. 1993, 36, 3371-3380.
19. Gillis, J. C.; Markham, A. Irbesartan, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in the Management of Hypertension. Drugs 1997, 54, 885-902.
20. Heisig, G. B.; Stodoler, F. H. 1,1-cyclobutane dicarboxylic acid and cyclobutane carboxylic acid. Org. Synth. 1943, 23, 16-20.
21. Conrad, M.; Zart, A. Über 1-phenyl-3-oxy-5-pyrazolonverbindungen. Chem. Ber. 1906, 39, 2282-2288.
22. Jnaneshwara, G. K.; Sudalai, A.; Deshpande, V. H. Palladium-catalysed Transfer Hydrogenation of Azobenzenes and Oximes using Ammonium Formate. J. Chem. Res. 1998, 160-161.
23. Naylor, E. M.; Chakravarty, P. K.; Costello, C. A.; Chang, R. S.; Chen, T.-B.; Faust, K. A.; Lotti, V. J.; Kivlighn, S. D.; Zingaro, G. J.; Siegl, P. K. S.; Wong, P. C.; Carini, D. J.; Wexler, R. R.; Patchett, A. A.; Greenlee, W. J. Potent imidazole Angiotensin II Antagonists: Acyl Sulfonamides and Acyl Sulfamides as Tetrazole Replacements. Bioorg. Med. Chem. Lett. 1994, 4, 69-74.
24. Chakravarty, P. K.; Greenlee, W. J.; Naylor, E. M.; Patchett, A. A.; Walsh, T. F. U.S. Patent 5, 126, 342, 1992.
25. (a) Wintersgill, H. P.; Warburton, P.; Bryson, S. E.; Ball, S. G.; Balmforth, A. J. Characterization of the angiotensin II receptor expressed by the human hepatoma cell line, PLC-PRF-5. Eur. J. Pharmacol. 1992, 227, 283-291.
26. 125I]AII (0.1 nM) on rat liver membranes).
27. 2 binding sites. Br. J. Pharmacol. 1991, 104, 425P.
28. 1 receptor antagonist. Br. J. Pharmacol. 1992, 107, 1173-1180.
29. i values of these selective ligands are as follows: losartan, >100 000 nM; irbesartan, >100 000 nM; PD 123319, 43 ± 1 nM; PD 123177, 5 ± 1 nM.
30. Noda, K.; Saad, Y.; Kinoshita, A.; Boyle, T. P.; Graham, R. M.; Husain, A.; Karnik, S. S. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J. Biol. Chem. 1995, 270, 2284-2289.
31. 1. J-Biol. Chem. 1995, 270, 14024-14030.
32. 2 Affinity. J. Med. Chem. 1994, 37, 2808-2824.
33. 1 Selective Angiotensin II Receptor Antagonists: 5-(Biphenyl-4-ylmethyl)pyrazoles. J. Med. Chem. 1997, 40, 547-558.
34. 2+-Oscillations in Vascular Myocytes from the Rat. Am. J. Physiol. 1996, 14, L637-L642.
35. 50 = 3 ± 1 nM).
36. 1 Receptor Binding Properties of Pyrazolidine-3,5-dione and Tetrahydropyridazine-3,6-dione Derivatives with Parent Antihypertensive Drug Irbesartan. In preparation.
37. Maeda, T.; Balakrishnan, K.; Qasim Mehdi, S. A Simple and Rapid Method for the Preparation of Plasma Membranes. Biochim. Biophys. Acta 1983, 737, 115-120.
38. 2+ Indicators with Greatly Improved Fluorescence Properties. J. Biol. Chem. 1985, 260, 3440-3450.